Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium
MWN-AI** Summary
Avacta Therapeutics (AIM: AVCT), a clinical-stage biopharmaceutical company, is poised to present groundbreaking data on its innovative dual-payload peptide drug conjugate (PDC) at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston on October 25. This pivotal research highlights Avacta's proprietary pre|CISION® technology, which uniquely enables the simultaneous delivery of two complementary anti-cancer agents using a single molecule.
The data demonstrates the proof of mechanism for Avacta's dual-payload PDC, a significant advancement in oncology treatment methodologies aimed at overcoming resistance in cancer therapy. Traditional approaches often employ drug combinations, and Avacta’s dual-payload solution allows these combinations to be selectively released directly within tumors, enhancing therapeutic efficacy while mitigating side effects.
Christina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta, emphasized that this development represents a major leap forward in cancer treatment. By leveraging fibroblast activation protein (FAP) cleavage, which is expressed in over 90% of solid tumors, the pre|CISION® platform can effectively release both a cytotoxic drug and a second drug targeting known resistance mechanisms. This novel implementation not only extends the existing pre|CISION® technology but provides a promising avenue for treating highly resistant cancers.
The upcoming presentation, titled "Discovery and characterization of novel pre|CISION® technology compounds delivering complementary dual payloads to the tumor microenvironment following FAP cleavage," will feature insights on this cutting-edge therapeutic approach. Avacta is quickly solidifying its place at the forefront of cancer therapeutics, with the potential to revolutionize treatment by concentrating drug efficacy specifically at tumor sites, thus promoting better patient tolerability and outcomes.
MWN-AI** Analysis
Avacta Therapeutics (AIM: AVCT) is poised for a significant breakthrough in oncology with its upcoming presentation at the 2025 EORTC-NCI-AACR International Conference. The unveiling of data on the first dual-payload peptide drug conjugate (PDC) that leverages the unique pre|CISION® platform could reshape treatment paradigms for cancer therapy, making this an opportune moment for investor consideration.
The dual-payload capability of the pre|CISION® platform signifies an innovative advancement, allowing the simultaneous delivery of two complementary drugs directly to tumors. This could enhance treatment effectiveness while potentially mitigating drug resistance—an increasingly critical challenge in oncology. Avacta's approach facilitates the selective release of these drugs via fibroblast activation protein (FAP) cleavage, which is expressed in over 90% of solid tumors. Thus, this method not only optimizes therapeutic impact within the tumor microenvironment but may also lower systemic toxicity.
Investors should take note of the broader implications of the technology. Avacta’s ability to combine multiple therapies within a single molecule could lead to expedited research and development timelines, increased collaboration opportunities, and eventual market access for a broader range of oncology products. Such advancements are typically well-received in the market, often leading to valuations reflective of the company’s innovation potential.
While the excitement surrounding the upcoming data presentation is palpable, potential investors should carefully manage their expectations. Early-stage biopharmaceutical investments are inherently volatile, susceptible to regulatory milestones, clinical trial outcomes, and market dynamics. However, given the comprehensive nature of pre|CISION® and increasing interest in combination therapies, Avacta represents a compelling consideration for those looking to invest in pioneering cancer therapies. Monitoring the response to the data set to be presented will be crucial for validating the company's market position and future growth trajectory.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LONDON and PHILADELPHIA, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION ® , a unique oncology delivery platform, today announces that the Company will present data on its first dual-payload peptide drug conjugate (PDC) at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston on October 25.
The data highlights the Company’s proprietary development enabling two complementary drugs to be delivered via a single pre|CISION ® medicine, representing the first dual payload PDC in the field. Data presented will be in vitro proof of mechanism for this platform innovation.
Drug combinations are commonly used in cancer therapy to improve outcomes and mitigate against resistance. This novel approach extends the pre|CISION ® technology to allow for the selective and controlled release of two cancer-targeting payloads directly in the tumor, from a single molecule via fibroblast activation protein (FAP) cleavage.
Previously, development of the pre|CISION ® platform focused on optimizing the delivery of single payloads to the tumor microenvironment leveraging the cleavage event by FAP, expressed in more than 90% of solid tumors. The new dual payload innovation expands the platform’s versatility, opening potential for more complex and effective oncology treatments.
Christina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta, said:
“The development of the first dual payload peptide drug conjugate platform marks a major leap forward in oncology therapy. This significantly extends the potential of our innovative pre|CISION ® platform by implementing combination cancer therapy in a single medicine.
“This new IP builds on the success of our FAP-EXd (AVA6103) program, where we invented a sustained release delivery mechanism with the platform. Our novel implementation of the platform extends this observation to now release two drugs from one pre|CISION ® molecule. The key factor here is our ability to target the tumor with a cytotoxic drug and attack the known resistance mechanism all in one cancer medicine. By building on the prior knowledge, we have now extended the reach to highly-resistant cancers by targeting key resistance mechanisms.
“This drug combination approach demonstrates the value we are building in our proprietary pre|CISION ® technology by further underlining its flexibility and unique potential to expand into novel oncology therapeutic approaches.
“We look forward to presenting the full data at the 2025 EORTC-NCI-AACR Symposium later this month.”
Event details are below and are available online on the 2025 EORTC-NCI-AACR Symposium website.
Title: Discovery and characterization of novel pre|CISION ® technology compounds delivering complementary dual payloads to the tumor microenvironment following FAP cleavage
Authors: Tom Clough, Alexa Kennedy, Ellen Watts, Iva Zlatareva, Folake Orafidiya, Hanna Buist, Jannah Jeon, Sophie Brown, Doug Sammon, Victoria Juskaite, David Jones, Dave Liebowitz, Michelle Morrow, Francis Wilson
Speaker: Francis Wilson
Session: Poster Session C
Date and Time : Saturday, October 25, 12:30-4pm
For further information from Avacta, please contact:
| Avacta Group plc Christina Coughlin, Chief Executive Officer | https://avacta.com/ via ICR Healthcare |
| Peel Hunt (Nomad and Joint Broker) James Steel / Chris Golden | www.peelhunt.com |
| Panmure Liberum (Joint Broker) Emma Earl / Will Goode / Mark Rogers Zeus (Joint Broker) James Hornigold / George Duxberry Dominic King | www.panmureliberum.com www.zeuscapital.co.uk |
| ICR Healthcare (Europe/UK media and investors) Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert | avacta@icrhealthcare.com |
| Investor Contact Renee Leck THRUST Strategic Communications | renee@thrustsc.com |
| Media Contact Carly Scaduto THRUST Strategic Communications | carly@thrustsc.com |
About Avacta – www.avacta.com
Avacta is a clinical stage life sciences company developing an innovative proprietary drug delivery peptide drug conjugate (PDC) platform, pre|CISION ® . The pre|CISION ® platform uniquely enables the repurposing of a range of oncology drugs as PDC payloads with the goal to significantly reduce toxicity and side effects for patients by concentrating the drug directly in the tumor.
About pre|CISION ®
The key aspect of pre|CISION ® is its peptide drug conjugates (PDC) technology. The combination of the cancer drug and the proprietary cleavable peptide (the PDC) is inert and incapable of entering cells and killing them until the peptide is specifically released within the tumor. The active payload in the pre|CISION ® PDC is released when the PDC comes into contact with the common tumor-associated protein, known as fibroblast activation protein (FAP), in the tumor. The release of the payload from the pre|CISION ® product directly in the tumor results in higher concentration of the drug at the tumor and lower blood and healthy tissue levels than standard systemic administration, offering the potential to improve efficacy and patient tolerability.
FAQ**
How does Avacta Group Plc AVCTF's new dual-payload peptide drug conjugate technology impact the future of cancer therapy in both London and Philadelphia?
What are the potential collaborations or market opportunities for Avacta Group Plc AVCTF in London and Philadelphia's growing biopharmaceutical sectors?
How might the advancements of Avacta Group Plc AVCTF's pre|CISION® technology influence investor perceptions in London compared to Philadelphia?
In what ways could Avacta Group Plc AVCTF’s findings presented in Boston on dual payloads reshape oncology research efforts in London and Philadelphia?
**MWN-AI FAQ is based on asking OpenAI questions about Avacta Group Plc (OTC: AVCTF).
NASDAQ: AVCTF
AVCTF Trading
0.0% G/L:
$0.9794 Last:
100 Volume:
$0.9794 Open:
